Trends in cardiovascular medicine: Update on cardiac transplantation

Truby, 2020, Advanced Heart Failure: Epidemiology, Diagnosis, and Therapeutic Approaches, JACC Heart Fail, 8, 523, 10.1016/j.jchf.2020.01.014 Colvin, 2020, OPTN/SRTR 2018 Annual Data Report: Heart, Am J Transplant, 20, 340, 10.1111/ajt.15676 Cogswell, 2020, An early investigation of outcomes with the new 2018 donor heart allocation system in the United States, J Heart Lung Transplant, 39, 1, 10.1016/j.healun.2019.11.002 Jawitz, 2020, Reassessing Recipient Mortality Under the New Heart Allocation System: An Updated UNOS Registry Analysis, JACC Heart Fail, 8, 548, 10.1016/j.jchf.2020.03.010 Parker, 2020, Practice Changes at U.S. Transplant Centers After the New Adult Heart Allocation Policy, J Am Coll Cardiol, 75, 2906, 10.1016/j.jacc.2020.01.066 Copeland, 2020, Donor heart and lung procurement: A consensus statement, J Heart Lung Transplant, 39, 501, 10.1016/j.healun.2020.03.020 Ardehali, 2015, Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial, Lancet, 385, 2577, 10.1016/S0140-6736(15)60261-6 Ozeki, 2007, Heart preservation using continuous ex vivo perfusion improves viability and functional recovery, Circulation, 71, 153, 10.1253/circj.71.153 Chan, 2017, Intermediate outcomes with ex-vivo allograft perfusion for heart transplantation, J Heart Lung Transplant, 36, 258, 10.1016/j.healun.2016.08.015 Gaffey, 2016, Transplantation of "high-risk" donor hearts: Implications for infection, J Thorac Cardiovasc Surg, 152, 213, 10.1016/j.jtcvs.2015.12.062 Schroder, 2019, Successful Utilization of Extended Criteria Donor (ECD) Hearts for Transplanation- Results of the OCS Heart Expand Trial to Evaluate the Effectiveness and Safety of the OCS Heart System to Preserve and Assess ECD Hearts for Transplantation, J Heart Lung Transplant, 38, S42, 10.1016/j.healun.2019.01.088 Gasink, 2006, Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients, JAMA, 296, 1843, 10.1001/jama.296.15.1843 Schlendorf, 2020, Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C, JAMA Cardiol, 5, 167, 10.1001/jamacardio.2019.4748 Kilic, 2020, Outcomes of Adult Heart Transplantation Using Hepatitis C-Positive Donors, J Am Heart Assoc, 9, 10.1161/JAHA.119.014495 Gidea, 2020, Increased early acute cellular rejection events in hepatitis C-positive heart transplantation, J Heart Lung Transplant, 10.1016/j.healun.2020.06.022 Nistal, 2021, Heart transplantation from controlled donation after circulatory death using thoracoabdominal normothermic regional perfusion and cold storage, J Card Surg, 36, 3421, 10.1111/jocs.15733 Abbasi, 2020, Donation After Circulatory Death, Heart Transplant US First JAMA, 323, 111 Messer, 2017, Outcome after heart transplantation from donation after circulatory-determined death donors, J Heart Lung Transplant, 36, 1311, 10.1016/j.healun.2017.10.021 Chew, 2019, Outcomes of Donation After Circulatory Death Heart Transplantation in Australia, J Am Coll Cardiol, 73, 1447, 10.1016/j.jacc.2018.12.067 Lund, 2016, The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant, J Heart Lung Transplant, 35, 1158, 10.1016/j.healun.2016.08.017 Nwakanma, 2007, Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era, Ann Thorac Surg, 84, 1556, 10.1016/j.athoracsur.2007.05.095 Timofeeva, 2020, Serum dilutions as a predictive biomarker for peri-operative desensitization: An exploratory approach to transplanting sensitized heart candidates, Transpl Immunol, 60, 10.1016/j.trim.2020.101274 Chih, 2016, Desensitization strategies in adult heart transplantation-Will persistence pay off?, J Heart Lung Transplant, 35, 962, 10.1016/j.healun.2016.03.021 Kobashigawa, 2018, The management of antibodies in heart transplantation: An ISHLT consensus document, J Heart Lung Transplant, 37, 537, 10.1016/j.healun.2018.01.1291 Agbor-Enoh, 2021, Cell-Free DNA to Detect Heart Allograft Acute Rejection, Circulation, 10.1161/CIRCULATIONAHA.120.049098 Holzhauser, 2020, Donor-derived cell-free DNA is associated with cardiac allograft vasculopathy, Clin Transplant, e14206 Crespo Leiro, 2015, Update Immune Monit Heart Transplanat Curr Transplant Rep, 2, 329 Schlendorf, 2018, Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies, J Heart Lung Transplant, 37, 763, 10.1016/j.healun.2018.01.1293 Patel, 2020, Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients, Am J Transplant Weston, 2009, Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants, Clin Transpl, 393 Vo, 2015, A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients, Transplantation, 99, 2356, 10.1097/TP.0000000000000741 Lorant, 2018, Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients, Am J Transplant, 18, 2752, 10.1111/ajt.14733 Vieira, 2004, Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics, Transplantation, 77, 542, 10.1097/01.TP.0000112934.12622.2B John, 1999, Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients, Circulation, 100, II229 Jordan, 2011, Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients, Am J Transplant, 11, 196, 10.1111/j.1600-6143.2010.03400.x